Novartis endocrine/metabolic news
Novartis filed a complaint in a German court in December through which it is seeking to block an assessment of its dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) which were launched before Germany's drug pricing law AMNOG came into effect. Last June, Germany's Federal Joint Committee (G-BA) said it would conduct benefit assessments of marketed DPP-4 inhibitors to treat Type II diabetes in its first assessment of any drugs that were launched before the law.
Novartis said in a statement that there are undisclosed "uncertainties" in whether the assessment process for the drugs meets legal criteria, which the pharma said must be examined by a court. A decision by the court on the permissibility of the pharma's claim is expected in the coming weeks. Dossiers for DPP-4 inhibitors marketed prior to AMNOG are due March 31. ...